RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$92.16
+6.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$86.53
From 52W high−21.65%
Volume2.26M
Market cap$6.39B
P/E (TTM)—
P/S (TTM)22.8x
Div yield—
Key dataNov 4, 2026
Open
$86.53
From 52W high
−21.65%
Volume
2.26M
Market cap
$6.39B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.7x
P/E (TTM)
—
RSI (14)
50.1
MomentumView details →
1D Return
+6.61%
YTD Return
−13.90%
SummaryUpdated Sep 1, 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in October 2017 and focuses exclusively on developing and commercializing therapeutics for rare genetic diseases of obesity. Rhythm has successfully transitioned from a development-stage company to a commercial enterprise with its flagship product IMCIVREE, which targets specific genetic pathways that control hunger and weight regulation. The company operates in the highly specialized field of rare genetic obesity disorders, serving patients with conditions that were previously considered untreatable.
Similar companies
Latest newsMore news →
Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.1 million, up 79.5% year over year, and a net loss of $42.4 million, or $0.61 per diluted share.1d agoRHYTHM PHARMACEUTICALS, INC. reported third-quarter 2026 global IMCIVREE net product revenue of $92.1 million, up 29% from the prior quarter.1d ago